Opinion

Video

NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib

William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importance of monitoring treatment response.

  1. Abemaciclib has been integrated into the NCCN Guidelines for certain patients with high-risk early-stage disease. What data is needed for ribociclib to find a similar position in the guidelines?
  2. What are the guideline recommendations for monitoring for response to systemic treatment in breast cancer? What outcomes are most important when monitoring response to treatment?
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo